<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.0" specific-use="sps-1.7" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
	<front>
		<journal-meta>
			<journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id>
			<journal-id journal-id-type="publisher-id">rbccv</journal-id>
			<journal-title-group>
				<journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title>
				<abbrev-journal-title abbrev-type="publisher">Braz. J. Cardiovasc.
					Surg.</abbrev-journal-title>
			</journal-title-group>
			<issn pub-type="ppub">0102-7638</issn>
			<issn pub-type="epub">1678-9741</issn>
			<publisher>
				<publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name>
			</publisher>
		</journal-meta>
		<article-meta>
			<article-id pub-id-type="doi">10.21470/1678-9741-2018-0130</article-id>
			<article-id pub-id-type="publisher-id">00005</article-id>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>ORIGINAL ARTICLE</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Which Method to Use for Surgical Ablation of Atrial Fibrillation
					Performed Concomitantly with Mitral Valve Surgery: Radiofrequency Ablation
						<italic>versus</italic> Cryoablation</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<name>
						<surname>Vural</surname>
						<given-names>Ünsal</given-names>
					</name>
					<xref ref-type="aff" rid="aff1">1</xref>
					<xref ref-type="corresp" rid="c1"/>
					<role>MD</role>
				</contrib>
				<contrib contrib-type="author">
					<name>
						<surname>Balc&#x0131;</surname>
						<given-names>Ahmet Yavuz</given-names>
					</name>
					<xref ref-type="aff" rid="aff1">1</xref>
					<role>MD</role>
				</contrib>
				<contrib contrib-type="author">
					<name>
						<surname>A&#x011F;lar</surname>
						<given-names>Ahmet Arif</given-names>
					</name>
					<xref ref-type="aff" rid="aff1">1</xref>
					<role>MD</role>
				</contrib>
				<contrib contrib-type="author">
					<name>
						<surname>K&#x0131;z&#x0131;lay</surname>
						<given-names>Mehmet</given-names>
					</name>
					<xref ref-type="aff" rid="aff1">1</xref>
					<role>MD</role>
				</contrib>
			</contrib-group>
				<aff id="aff1">
					<label>1</label>
					<institution content-type="orgname">Dr. Siyami Ersek Thoracic and Cardiovascular
						Surgery Training and Research Hospital</institution>
					<institution content-type="orgdiv1">Department of Cardiovascular
						Surgery</institution>
					<addr-line>
        <named-content content-type="city">Istanbul</named-content>
					</addr-line>
					<country country="TR">Turkey</country>
					<institution content-type="original">Department of Cardiovascular Surgery, Dr.
						Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research
						Hospital, Istanbul, Turkey.</institution>
				</aff>
			<author-notes>
				<corresp id="c1">Correspondence Address: Ünsal Vural, Selimiye Mh. Tibbiye Cd.
					No:13, 34668 - Uskudar, Istanbul, Turkey. E-mail:
						<email>unsalvural@gmail.com</email></corresp>
				<fn fn-type="conflict">
					<p>No conflict of interest.</p>
				</fn>
			</author-notes>
			<pub-date pub-type="epub-ppub">
				<season>Nov-Dec</season>
				<year>2018</year>
			</pub-date>
			<volume>33</volume>
			<issue>6</issue>
			<fpage>542</fpage>
			<lpage>552</lpage>
			<history>
				<date date-type="received">
					<day>05</day>
					<month>05</month>
					<year>2018</year>
				</date>
				<date date-type="accepted">
					<day>08</day>
					<month>07</month>
					<year>2018</year>
				</date>
			</history>
			<permissions>
				<license license-type="open-access"
					xlink:href="http://creativecommons.org/licenses/by/4.0/" xml:lang="en">
					<license-p>This is an Open Access article distributed under the terms of the
						Creative Commons Attribution License, which permits unrestricted use,
						distribution, and reproduction in any medium, provided the original work is
						properly cited.</license-p>
				</license>
			</permissions>
			<abstract>
				<title>Abstract</title>
				<sec>
					<title>Objective:</title>
					<p>The effects of energy source on the maintenance of sinus rhythm and the
						contribution of demographic characteristics to the case selection in
						patients submitted to ablation performed concurrently with mitral valve
						surgery were analyzed.</p>
				</sec>
				<sec>
					<title>Methods:</title>
					<p>Cryothermal (n=42; 43.8%) and radiofrequency (n=54; 56.3%) energy were
						employed in 96 patients submitted to mitral valve replacement and Cox maze
						IV procedure. Patients were called for control visits between 15 days and 12
						months after discharge. The causal relationship between recurrence of atrial
						fibrillation and factors such as left atrial diameter, C-reactive protein,
						hypertension, left ventricular ejection fraction, chronic obstructive
						pulmonary disease, and body mass index was determined.</p>
				</sec>
				<sec>
					<title>Results:</title>
					<p>Maintenance rates of the sinus rhythm with radiofrequency and cryoablation
						were 97.6% and 96.3%, respectively, in the first postoperative month,
						whereas at the 12<sup>th</sup> postoperative month were 88.1% and 83.3%. No
						significant difference was found between groups in relation to the energy
						source. Sensitivity and specificity for left atrial diameter with a cut-off
						value of 50.5 mm were 85.7% and 70.7%, respectively. Sensitivity and
						specificity for C-reactive protein with a cut-off value of 12 mg/dL on the
							15<sup>th</sup> postoperative day were 83.3% and 88.9%, respectively.
						The effect of body mass index on atrial fibrillation recurrence was 3.2
						times. Sensitivity and specificity for left ventricular ejection fraction
						37% cut-off value were 96.3% and 11.4%, respectively. Atrial fibrillation in
						hypertensive cases was 5.3 times more. In patients with chronic obstructive
						pulmonary disease, recurrence of atrial fibrillation was 40%. The causal
						relation between recurrence of atrial fibrillation and the studied factors
						was established.</p>
				</sec>
				<sec>
					<title>Conclusion:</title>
					<p>Demographic characteristics have a significant impact on ablation efficiency,
						while the type of energy source does not.</p>
				</sec>
			</abstract>
			<kwd-group xml:lang="en">
				<title>Keywords:</title>
				<kwd>Mitral Valve/surgery</kwd>
				<kwd>Cryosurgery</kwd>
				<kwd>Catheter Ablation</kwd>
				<kwd>Ablation</kwd>
				<kwd>Ablation Techniques</kwd>
			</kwd-group>
		</article-meta>
	</front>
	<body>
		<table-wrap id="t3">
						<alternatives>
							<graphic xlink:href="t0.jpg"/>
			<table frame="hsides" rules="groups">
				<colgroup>
					<col width="10%"/>
					<col width="38%"/>
					<col width="05%"/>
					<col width="10%"/>
					<col width="37%"/>
				</colgroup>
				<thead>
					<tr>
						<th align="left" colspan="2" style="background-color:#eaeaea">Abbreviations,
							acronyms &amp; symbols</th>
						<th align="center">&#x00A0;</th>
						<th align="center" colspan="2" style="background-color:#eaeaea"
							>&#x00A0;</th>
					</tr>
				</thead>
				<tbody>
					<tr>
						<td align="left" style="background-color:#eaeaea"><bold>AF</bold></td>
						<td align="left" style="background-color:#eaeaea"><bold>= Atrial
								fibrillation</bold></td>
						<td align="left">&#x00A0;</td>
						<td align="left" style="background-color:#eaeaea"><bold>ECG</bold></td>
						<td align="left" style="background-color:#eaeaea"><bold>=
								Electrocardiogram</bold></td>
					</tr>
					<tr>
						<td align="left" style="background-color:#eaeaea"><bold>ACC</bold></td>
						<td align="left" style="background-color:#eaeaea"><bold>= American College
								of Cardiology</bold></td>
						<td align="left">&#x00A0;</td>
						<td align="left" style="background-color:#eaeaea"><bold>EHRA</bold></td>
						<td align="left" style="background-color:#eaeaea"><bold>= European Heart
								Rhythm Association</bold></td>
					</tr>
					<tr>
						<td align="left" style="background-color:#eaeaea"><bold>AHA</bold></td>
						<td align="left" style="background-color:#eaeaea"><bold>= American Heart
								Association</bold></td>
						<td align="left">&#x00A0;</td>
						<td align="left" style="background-color:#eaeaea"><bold>ESC</bold></td>
						<td align="left" style="background-color:#eaeaea"><bold>= European Society
								of Cardiology</bold></td>
					</tr>
					<tr>
						<td align="left" style="background-color:#eaeaea"><bold>BMI</bold></td>
						<td align="left" style="background-color:#eaeaea"><bold>= Body mass
								index</bold></td>
						<td align="left">&#x00A0;</td>
						<td align="left" style="background-color:#eaeaea"><bold>HRS</bold></td>
						<td align="left" style="background-color:#eaeaea"><bold>= Heart Rhythm
								Society</bold></td>
					</tr>
					<tr>
						<td align="left" style="background-color:#eaeaea"><bold>COPD</bold></td>
						<td align="left" style="background-color:#eaeaea"><bold>= Chronic
								obstructive pulmonary disease</bold></td>
						<td align="left">&#x00A0;</td>
						<td align="left" style="background-color:#eaeaea"><bold>LVEF</bold></td>
						<td align="left" style="background-color:#eaeaea"><bold>= Left ventricular
								ejection fraction</bold></td>
					</tr>
					<tr>
						<td align="left" style="background-color:#eaeaea"><bold>CrA</bold></td>
						<td align="left" style="background-color:#eaeaea"><bold>= Cryothermal
								ablation</bold></td>
						<td align="left">&#x00A0;</td>
						<td align="left" style="background-color:#eaeaea"><bold>RFA</bold></td>
						<td align="left" style="background-color:#eaeaea"><bold>= Radiofrequency
								ablation</bold></td>
					</tr>
					<tr>
						<td align="left" style="background-color:#eaeaea"><bold>CRP</bold></td>
						<td align="left" style="background-color:#eaeaea"><bold>= C-reactive
								protein</bold></td>
						<td align="left">&#x00A0;</td>
						<td align="left" style="background-color:#eaeaea"><bold>ROC</bold></td>
						<td align="left" style="background-color:#eaeaea"><bold>= Receiver operating
								characteristic</bold></td>
					</tr>
					<tr>
						<td align="left" style="background-color:#eaeaea"><bold>ECAS</bold></td>
						<td align="left" style="background-color:#eaeaea"><bold>= European Cardiac
								Arrhythmia Society</bold></td>
						<td align="left">&#x00A0;</td>
						<td align="left" style="background-color:#eaeaea">&#x00A0;</td>
						<td align="left" style="background-color:#eaeaea">&#x00A0;</td>
					</tr>
				</tbody>
			</table>
		</alternatives>
		</table-wrap>
		<sec sec-type="intro">
			<title>INTRODUCTION</title>
			<p>Atrial fibrillation (AF) is the most common cause of arrhythmia and its incidence
				increases with age. The prevalence in developed countries is 1.5-2%. It reaches 17%
				in advanced age and 80% for mitral valve disease<sup>[</sup><xref ref-type="bibr"
					rid="B1">1</xref><sup>]</sup>. It increases the risk of thromboembolism by
				sixteen times (the incidence of stroke is 5-10% in patients with AF whereas it is
				0.3% in the normal population)<sup>[</sup><xref ref-type="bibr" rid="B2"
					>2</xref><sup>]</sup>. It is known that cardiovascular mortality is doubled by
					AF<sup>[</sup><xref ref-type="bibr" rid="B2">2</xref><sup>]</sup>. According to
				the American Heart Association (AHA), 70,000 patients a year are referred to
				hospitals due to AF<sup>[</sup><xref ref-type="bibr" rid="B2">2</xref><sup>]</sup>.
				Additional complications such as hemodynamic instability, palpitation, fainting,
				increased duration of total hospitalization, and side effects due to pharmacological
				treatment applied are also observed<sup>[</sup><xref ref-type="bibr" rid="B3"
					>3</xref><sup>]</sup>. For this reason, the Heart Rhythm Society (HRS)/ European
				Heart Rhythm Association (EHRA)/ European Cardiac Arrhythmia Society (ECAS)
				guidelines recommend treatment of AF with ablation if cardiac surgery is performed
				for concomitant pathology<sup>[</sup><xref ref-type="bibr" rid="B4"
					>4</xref><sup>]</sup>.</p>
			<p>Since Cox's surgical AF ablation reported the cut-and-sew technique in 1987, only 38%
				of the valve replacement procedures have been coupled with AF
					ablation<sup>[</sup><xref ref-type="bibr" rid="B5">5</xref><sup>]</sup>.
				Although it was reported in the first years that sinus rhythm and conduction
				pathways were preserved, this did not relieve surgeon's concerns. In the following
				years, there was renewed interest among surgeons for maze procedure, after reporting
				that alternative sources of energy (<italic>e.g</italic>., radiofrequency,
				ultrasound and cryothermal) could create transmural lesions. The purpose of the
				ablation is to synchronize the atrium and the ventricles by inhibiting reentry in
				macroreentrant circuits and reducing the surface area to which the electrical
				activity of the atrium is confined, in addition to ablation of focal atrial
					triggers<sup>[</sup><xref ref-type="bibr" rid="B6">6</xref><sup>]</sup>. In
				order to the procedure to be effective, it is important to create transmural
				lesions, not disrupt the atrium functions and damage surrounding
					tissues<sup>[</sup><xref ref-type="bibr" rid="B7">7</xref><sup>]</sup>.</p>
			<p>Although there are many studies showing the success of the Cox maze IV method, only a
				small number of studies comparing energy sources and focused on the causes of AF
				recurrence is present. Despite the initial successful results with bipolar cautery,
				it had disadvantages such as difficulties in handling and controlling energy, clot
				formation in the atrium, rupture of the atrium, and damage to surrounding tissues.
				Due to the risk of esophageal and coronary artery injury, in particular, the method
				has gradually given way to the radiofrequency ablation (RFA). Radiofrequency is a
				hyperthermic energy, producing transmural lesions. Alternatively, cryothermal
				ablation (CrA) produces lesions similar to the classical Cox maze procedure by
				freezing tissues and causing cellular damage at temperatures of −60/−70°C with
				nitrous oxide supplementation. Despite the advantages of the formation of transmural
				lesions and low risk of perforation and thromboembolism, the length of the
				application period is a disadvantage.</p>
			<p>In our study, we investigated the maintenance rate of postoperative sinus rhythm and
				the factors affecting it in cases involving concomitant AF ablation with mitral
				valve surgery and tried to determine whether there is a causal relationship with the
				energy source (RFA and CrA) used. We also tried to determine the cumulative effect
				of the risk factors on the maintenance of sinus rhythm and their contribution to
				appropriate case selection.</p>
		</sec>
		<sec sec-type="methods">
			<title>METHODS</title>
			<sec>
				<title>Patients</title>
				<p>The study was planned as a retrospective case-control study with the approval of
					our institution's ethics committee. The study included 96 patients who underwent
					either RFA or CrA procedures concomitant with mitral valve replacement and
					tricuspid valve repair between June 2014 and May 2018. The cases were randomly
					selected among patients with preoperative AF rhythm at least for three months
					(persistent AF) without previous history of ablation and underwent mitral and/or
					tricuspid valve surgery, concomitantly with surgical AF ablation. Cases with a
					history of such diseases leading to dysrhythmia through electrolyte
					irregularities as diabetes mellitus, thyroid and renal dysfunction, and cases of
					infective endocarditis requiring complex treatment were excluded. In the study,
					information from the hospital patient database and the patient's telephone
					records were used. The operations were performed by three different primary
					surgeons. All operations were performed under cardiopulmonary bypass. Cases
					requiring additional intervention were excluded from the study. The mean age of
					the cases was 50.1 (Max-Min = 27-68; 52.1% female). In 89 cases, median
					sternotomy was performed whereas right mini-thoracotomy was the approach of
					choice in seven cases. Electrocardiogram (ECG) and/or Holter recordings obtained
					at follow-up visits performed on the 1<sup>st</sup>, 3<sup>rd</sup>,
						6<sup>th</sup> and 15<sup>th</sup> postoperative days and 12<sup>th</sup>
					postoperative month by patients following one-week hospitalization were used to
					investigate the AF recurrence. A 24-hour Holter monitoring was performed in
					cases with a 6-month interval. At the control visits, the presence of acute
					inflammation, infection and related complications were evaluated with blood
					tests and physical examination (<xref ref-type="table" rid="t1">Table
					1</xref>).</p>
				<table-wrap id="t1">
					<label>Table 1</label>
					<caption>
						<title>Demographical characteristics of the cases</title>
					</caption>
						<alternatives>
							<graphic xlink:href="t1.jpg"/>
					<table frame="hsides" rules="all">
						<colgroup>
							<col width="34%"/>
							<col width="24%"/>
							<col width="8%"/>
							<col width="8%"/>
							<col width="8%"/>
							<col width="8%"/>
							<col width="8%"/>
						</colgroup>
						<thead>
							<tr>
								<th align="left" colspan="2" rowspan="3">&#x00A0;</th>
								<th align="center" colspan="5">Ablation type</th>
							</tr>
							<tr>
								<th colspan="2">RFA (n=54)</th>
								<th colspan="3">CrA (n=42)</th>
							</tr>
							<tr>
								<th>Mean</th>
								<th>SD</th>
								<th>Mean</th>
								<th>SD</th>
								<th><italic>P</italic>-value</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td align="left" colspan="2">Age (years)</td>
								<td align="center">48</td>
								<td align="center">9</td>
								<td align="center">53</td>
								<td align="center">9</td>
								<td align="center">0.016<xref ref-type="table-fn" rid="TFN01"
											><sup>a</sup></xref></td>
							</tr>
							<tr>
								<td align="left" colspan="2">Left atrium diameter (mm)</td>
								<td align="center">48.98</td>
								<td align="center">5.45</td>
								<td align="center">49.05</td>
								<td align="center">5.72</td>
								<td align="center">0.954<xref ref-type="table-fn" rid="TFN01"
											><sup>a</sup></xref></td>
							</tr>
							<tr>
								<td align="left" colspan="2">Intensive Care Unit (days)</td>
								<td align="center">1</td>
								<td align="center">1</td>
								<td align="center">1</td>
								<td align="center">__</td>
								<td align="center">0.145<xref ref-type="table-fn" rid="TFN01"
											><sup>a</sup></xref></td>
							</tr>
							<tr>
								<td align="left" colspan="2">Hospitalization (days)</td>
								<td align="center">6</td>
								<td align="center">1</td>
								<td align="center">6</td>
								<td align="center">1</td>
								<td align="center">0.509<xref ref-type="table-fn" rid="TFN01"
											><sup>a</sup></xref></td>
							</tr>
							<tr>
								<td align="left" colspan="2">Aortic cross-clamping time (min)</td>
								<td align="center">63</td>
								<td align="center">12</td>
								<td align="center">68</td>
								<td align="center">11</td>
								<td align="center">0.035<xref ref-type="table-fn" rid="TFN01"
											><sup>a</sup></xref></td>
							</tr>
							<tr>
								<td align="left" colspan="2">Total cardiopulmonary bypass time
									(min)</td>
								<td align="center">66</td>
								<td align="center">10</td>
								<td align="center">83</td>
								<td align="center">10</td>
								<td align="center">0.001<xref ref-type="table-fn" rid="TFN01"
											><sup>a</sup></xref></td>
							</tr>
							<tr>
								<td align="left" colspan="2">Left ventricular ejection fraction
									(%)</td>
								<td align="center">48.78</td>
								<td align="center">6.52</td>
								<td align="center">50.07</td>
								<td align="center">6.13</td>
								<td align="center">0.325<xref ref-type="table-fn" rid="TFN01"
											><sup>a</sup></xref></td>
							</tr>
							<tr>
								<td align="left" colspan="2">Preoperative CRP (mg/dL)</td>
								<td align="center">4.6</td>
								<td align="center">1.6</td>
								<td align="center">4.5</td>
								<td align="center">1.5</td>
								<td align="center">0.864<xref ref-type="table-fn" rid="TFN01"
											><sup>a</sup></xref></td>
							</tr>
							<tr>
								<td align="left" colspan="2">&#x00A0;</td>
								<td align="center"><bold>n</bold></td>
								<td align="center"><bold>%</bold></td>
								<td align="center"><bold>n</bold></td>
								<td align="center"><bold>%</bold></td>
								<td align="center">&#x00A0;</td>
							</tr>
							<tr>
								<td align="left" rowspan="4">Body mass index (kg/m<sup>2</sup>)</td>
								<td align="center">&lt;25</td>
								<td align="center">25</td>
								<td align="center">54.3</td>
								<td align="center">21</td>
								<td align="center">45.7</td>
								<td align="center" rowspan="4">0.395<xref ref-type="table-fn"
										rid="TFN01"><sup>a</sup></xref></td>
							</tr>
							<tr>
								<td align="center">25-29</td>
								<td align="center">20</td>
								<td align="center">55.6</td>
								<td align="center">16</td>
								<td align="center">44.4</td>
							</tr>
							<tr>
								<td align="center">30-35</td>
								<td align="center">6</td>
								<td align="center">54.5</td>
								<td align="center">5</td>
								<td align="center">45.5</td>
							</tr>
							<tr>
								<td align="center">&gt;35</td>
								<td align="center">3</td>
								<td align="center">100</td>
								<td align="center">__</td>
								<td align="center">__</td>
							</tr>
							<tr>
								<td align="left" rowspan="2">Gender</td>
								<td align="center">Female</td>
								<td align="center">24</td>
								<td align="center">48</td>
								<td align="center">26</td>
								<td align="center">52</td>
								<td align="center" rowspan="2">0.089<xref ref-type="table-fn"
										rid="TFN02"><sup>b</sup></xref></td>
							</tr>
							<tr>
								<td align="center">Male</td>
								<td align="center">30</td>
								<td align="center">65.2</td>
								<td align="center">16</td>
								<td align="center">34.8</td>
							</tr>
							<tr>
								<td align="left" rowspan="2">Surgical procedure</td>
								<td align="center">MVR</td>
								<td align="center">29</td>
								<td align="center">65.9</td>
								<td align="center">15</td>
								<td align="center">34.1</td>
								<td align="center" rowspan="2">0.079<xref ref-type="table-fn"
										rid="TFN02"><sup>b</sup></xref></td>
							</tr>
							<tr>
								<td align="center">MVR+TDVGA</td>
								<td align="center">25</td>
								<td align="center">48.1</td>
								<td align="center">27</td>
								<td align="center">51.9</td>
							</tr>
							<tr>
								<td align="left" rowspan="2">Previous stroke</td>
								<td align="center">Unavailable</td>
								<td align="center">52</td>
								<td align="center">55.9</td>
								<td align="center">41</td>
								<td align="center">44.1</td>
								<td align="center" rowspan="2">0.712<xref ref-type="table-fn"
										rid="TFN02"><sup>b</sup></xref></td>
							</tr>
							<tr>
								<td align="center">Available</td>
								<td align="center">2</td>
								<td align="center">66.7</td>
								<td align="center">1</td>
								<td align="center">33.3</td>
							</tr>
							<tr>
								<td align="left" rowspan="2">Postoperative pacemaker</td>
								<td align="center">Unavailable</td>
								<td align="center">53</td>
								<td align="center">55.8</td>
								<td align="center">42</td>
								<td align="center">44.2</td>
								<td align="center" rowspan="2">0.375<xref ref-type="table-fn"
										rid="TFN02"><sup>b</sup></xref></td>
							</tr>
							<tr>
								<td align="center">Available</td>
								<td align="center">1</td>
								<td align="center">100</td>
								<td align="center">__</td>
								<td align="center">__</td>
							</tr>
							<tr>
								<td align="left" rowspan="2">Chronic obstructive pulmonary
									disease</td>
								<td align="center">Unavailable</td>
								<td align="center">47</td>
								<td align="center">54.7</td>
								<td align="center">39</td>
								<td align="center">45.3</td>
								<td align="center" rowspan="2">0.356<xref ref-type="table-fn"
										rid="TFN02"><sup>b</sup></xref></td>
							</tr>
							<tr>
								<td align="center">Available</td>
								<td align="center">7</td>
								<td align="center">70</td>
								<td align="center">3</td>
								<td align="center">30</td>
							</tr>
							<tr>
								<td align="left" rowspan="4">New York Heart Association functional
									class</td>
								<td align="center">I</td>
								<td align="center">10</td>
								<td align="center">41.7</td>
								<td align="center">14</td>
								<td align="center">58.3</td>
								<td align="center" rowspan="4">0.13<xref ref-type="table-fn"
										rid="TFN01"><sup>a</sup></xref></td>
							</tr>
							<tr>
								<td align="center">II</td>
								<td align="center">30</td>
								<td align="center">60</td>
								<td align="center">20</td>
								<td align="center">40</td>
							</tr>
							<tr>
								<td align="center">III</td>
								<td align="center">14</td>
								<td align="center">63.6</td>
								<td align="center">8</td>
								<td align="center">36.4</td>
							</tr>
							<tr>
								<td align="center">IV</td>
								<td align="center">__</td>
								<td align="center">__</td>
								<td align="center">__</td>
								<td align="center">__</td>
							</tr>
							<tr>
								<td align="left" rowspan="2">Hypertension</td>
								<td align="center">Unavailable</td>
								<td align="center">45</td>
								<td align="center">55.6</td>
								<td align="center">36</td>
								<td align="center">44.4</td>
								<td align="center" rowspan="2">0.75<xref ref-type="table-fn"
										rid="TFN02"><sup>b</sup></xref></td>
							</tr>
							<tr>
								<td align="center">Available</td>
								<td align="center">9</td>
								<td align="center">60</td>
								<td align="center">6</td>
								<td align="center">40</td>
							</tr>
						</tbody>
					</table>
				</alternatives>
					<table-wrap-foot>
						<fn id="TFN01">
							<label>a</label>
							<p>=independent t-test;</p>
						</fn>
						<fn id="TFN02">
							<label>b</label>
							<p>=Chi-square test; Fisher's exact test, continuity correction
								test.</p>
						</fn>
						<fn id="TFN03">
							<p>CrA=cryoablation; MVR+TDVGA=mitral valve replacement+tricuspid De
								Vega annuloplasty; RFA=radiofrequency ablation; SD=standard
								deviation</p>
						</fn>
					</table-wrap-foot>
				</table-wrap>
			</sec>
			<sec>
				<title>Ablation Method</title>
				<p>Cryothermal energy (AtriCure<sup>&#x00AE;</sup> cryoICE BOX surgical ablation
					system, model cryoICE BOX2-230 VAC) was used as an energy source for ablation in
					42 (43.8%) patients, while bipolar radiofrequency energy was used in 54 (56.3%)
					patients (AtriCure<sup>&#x00AE;</sup> Articulating Jaw, Isolator Synergy
						Access<sup>&#x00AE;</sup>). In all cases, the biatrial ablation technique
					shown in <xref ref-type="fig" rid="f1">Figure 1</xref> was applied. Access to
					atrioventricular valves and/or atria done through superior septal incision in
					the cases with median sternotomy, while in those with the thoracotomy was
					performed through the separate left and right atriotomies. Because of the ease
					of manipulation, CrA was preferred in cases of thoracotomy. Ablation procedure
					was performed based on the incision lines described in <xref ref-type="fig"
						rid="f1">Figure 1</xref>. The same procedure was preferred for both
					cryothermal and radiofrequency ablation. Ablation was performed prior to valve
					replacement and division of the left atrial appendage. The left atrial appendix
					was closed using 4.0 Prolene sutures. Ablation procedure took 10-15 min for RFA
					and 25-30 min for CrA.</p>
				<p>
					<fig id="f1">
						<label>Fig. 1</label>
						<caption>
							<title>Schematic drawing on ablation technique used in the
								study.</title>
						</caption>
						<graphic xlink:href="0102-7638-rbccv-33-06-0542-gf01.jpg"/>
					</fig>
				</p>
			</sec>
			<sec>
				<title>Follow-up Protocol</title>
				<p>In the first 3 postoperative days, all cases were followed by continuous ECG
					monitoring. Perioperative amiodarone hydrochloride infusion (intravenous in 5%
					dextrose, 10-15 mg/kg/24h) was started according to the protocol applied in our
					clinic. Treatment with amiodarone hydrochloride (200 mg twice a day
					postoperative) and indomethacin (25 mg twice a day p.o.) was continued for 3
					months in patients with oral intake. Three months later, metoprolol tartrate
					therapy (100 mg once a day postoperative) was started. During an average of 7
					days of hospitalization, the heart rate was followed by daily ECG recording.
					Patients were called for control visits on the 1<sup>st</sup>, 3<sup>rd</sup>,
						6<sup>th</sup> and 15<sup>th</sup> postoperative days and 12 months after
					discharge. The patients were examined in terms of inflammation, infection,
					stroke and rhythm disturbances, as well as the need for further treatment.
					Rhythm follow-up was done with ECG recording in the routine with Holter
					monitoring in the 6<sup>th</sup> and 12<sup>th</sup> months. In cases with
					permanent pacemaker insertion due to complete atrioventricular block developed
					postoperatively, pacemaker follow-up was performed. Antiarrhythmic therapy of
					patients with a heart rate below 60 beats/min was discontinued. In patients with
					recurrent AF, antiarrhythmic therapy was restarted and 24-hour ECG monitoring
					was performed. Electrical cardioversion was applied to cases detected early.
					Patients who did not respond to maximal antiarrhythmic treatment and electrical
					cardioversion were referred to cardiology for catheter ablation</p>
			</sec>
			<sec>
				<title>Statistical Analysis</title>
				<p>Statistical Package for Social Sciences Statistical Software version 18.0 (SPSS
					Inc., Chicago, Il, USA) was used in our single-center retrospective case-control
					study. Continuous variables were expressed as mean and standard deviation, while
					Student t-test was used for the comparisons. Paired samples t-test was used in
					the analysis of the dependent data. Categorical and nominal variables were
					expressed in terms of number and percentage (%). The relationship status was
					determined by chi-square, Fisher's exact test, and continuity correction tests.
					Multinomial logistic and linear regression analyzes were used to determine the
					factors affecting maintenance of sinus rhythm by analyzing age, gender, left
					ventricular ejection fraction (LVEF), the presence of chronic obstructive
					pulmonary disease (COPD), type of energy source, length of hospital stay, body
					mass index (BMI), left atrial diameter, cross-clamping time and C-reactive
					protein (CRP) levels. The cut-off points of risk factors detected in cases with
					postoperative AF recurrence were determined by receiver operating characteristic
					(ROC) analysis. The cumulative effect of AF at one year and the significance
					level by months were tested by Kaplan-Meier survey analysis. The results were
					considered significant when the two-sided <italic>P</italic>-value was
					&lt;0.05.</p>
			</sec>
		</sec>
		<sec sec-type="results">
			<title>RESULTS</title>
			<p>Bipolar RFA was used in 54 patients (56.3%, 24 females) while CrA was used in 42
				patients (43.8%, 26 females). There were no significant differences between the
				demographic characteristics of the groups, except age and cross-clamping time.
				Distribution of demographic and operative characteristics is shown in <xref
					ref-type="table" rid="t1">Table 1</xref>. Maintenance rates of sinus rhythm in
				the CrA and RFA groups were 97.6% and 96.3% in the early postoperative period, and
				88.1% and 83.3% in the 12<sup>th</sup> postoperative month (mean 85.4%),
				respectively. No significant difference was found between the groups in relation to
				the energy source used in the early postoperative period and after 12 months
				(Mentel-Cox <italic>P</italic>=0.455; <xref ref-type="fig" rid="f2">Figure
				2</xref>). There was no mortality during follow-up. In the CrA group, postoperative
				transient cerebral ischemic attack was observed in one (2.3%) case. In the bipolar
				RFA group, perioperative posterior wall rupture was observed in one (1.8%) case,
				hemiplegia in one (1.8%) case and permanent pacemaker need in one (1.8%) case. The
				wall rupture was sutured without additional complications.</p>
			<p>
				<fig id="f2">
					<label>Fig. 2</label>
					<caption>
						<title>Survival analysis of cases according to the energy source used.
							AF=atrial fibrillation; CrA=cryothermal ablation; RFA=radiofrequency
							ablation</title>
					</caption>
					<graphic xlink:href="0102-7638-rbccv-33-06-0542-gf02.jpg"/>
				</fig>
			</p>
			<p>In the postoperative follow-up, the causal relationship between AF recurrence and
				left atrial diameter, CRP level, hypertension, LVEF, COPD and BMI was found (<xref
					ref-type="table" rid="t2">Table 2</xref>; <xref ref-type="fig" rid="f3">Figures
					3</xref>-<xref ref-type="fig" rid="f6">6</xref>;
				<italic>P</italic>&lt;0.05).</p>
			<table-wrap id="t2">
				<label>Table 2</label>
				<caption>
					<title>Distribution of risk parameters in relation to postoperative atrial
						fibrillation status.</title>
				</caption>
						<alternatives>
							<graphic xlink:href="t2.jpg"/>
				<table frame="hsides" rules="all">
					<colgroup>
						<col width="34%"/>
						<col width="25%"/>
						<col width="8%"/>
						<col width="8%"/>
						<col width="8%"/>
						<col width="8%"/>
						<col width="8%"/>
					</colgroup>
					<thead>
						<tr>
							<th align="left" colspan="2" rowspan="3">&#x00A0;</th>
							<th align="center" colspan="5">AF status</th>
						</tr>
						<tr>
							<th colspan="2">Unavailable</th>
							<th colspan="2">Available</th>
							<th rowspan="2"><italic>P</italic>-value</th>
						</tr>
						<tr>
							<th>Mean</th>
							<th>SD</th>
							<th>Mean</th>
							<th>SD</th>
						</tr>
					</thead>
					<tbody>
						<tr>
							<td align="left" colspan="2">Age (years)</td>
							<td align="center">50</td>
							<td align="center">9</td>
							<td align="center">50</td>
							<td align="center">10</td>
							<td align="center">0.921<xref ref-type="table-fn" rid="TFN04"
										><sup>a</sup></xref></td>
						</tr>
						<tr>
							<td align="left" colspan="2">Left atrium diameter (mm)</td>
							<td align="center">48.1</td>
							<td align="center">5.11</td>
							<td align="center">54.36</td>
							<td align="center">5.06</td>
							<td align="center">0.001<xref ref-type="table-fn" rid="TFN04"
										><sup>a</sup></xref></td>
						</tr>
						<tr>
							<td align="left" colspan="2">Intensive Care Unit (days)</td>
							<td align="center">1</td>
							<td align="center">1</td>
							<td align="center">1</td>
							<td align="center">1</td>
							<td align="center">0.685<xref ref-type="table-fn" rid="TFN04"
										><sup>a</sup></xref></td>
						</tr>
						<tr>
							<td align="left" colspan="2">Hospitalization (days)</td>
							<td align="center">6</td>
							<td align="center">1</td>
							<td align="center">6</td>
							<td align="center">1</td>
							<td align="center">0.843<xref ref-type="table-fn" rid="TFN04"
										><sup>a</sup></xref></td>
						</tr>
						<tr>
							<td align="left" colspan="2">Aortic cross-clamping time (min)</td>
							<td align="center">64</td>
							<td align="center">11</td>
							<td align="center">68</td>
							<td align="center">14</td>
							<td align="center">0.236<xref ref-type="table-fn" rid="TFN04"
										><sup>a</sup></xref></td>
						</tr>
						<tr>
							<td align="left" colspan="2">Cardiopulmonary bypass time (min)</td>
							<td align="center">75</td>
							<td align="center">13</td>
							<td align="center">68</td>
							<td align="center">16</td>
							<td align="center">0.08<xref ref-type="table-fn" rid="TFN04"
										><sup>a</sup></xref></td>
						</tr>
						<tr>
							<td align="left" colspan="2">Left ventricular ejection fraction (%)</td>
							<td align="center">50.44</td>
							<td align="center">5.85</td>
							<td align="center">42.93</td>
							<td align="center">5.46</td>
							<td align="center">0.001<xref ref-type="table-fn" rid="TFN04"
										><sup>a</sup></xref></td>
						</tr>
						<tr>
							<td align="left" colspan="2">&#x00A0;</td>
							<td align="center"><bold>n</bold></td>
							<td align="center"><bold>%</bold></td>
							<td align="center"><bold>n</bold></td>
							<td align="center"><bold>%</bold></td>
							<td align="center">&#x00A0;</td>
						</tr>
						<tr>
							<td align="left" rowspan="4">Body mass index (kg/m<sup>2</sup>)</td>
							<td align="center">&lt;25</td>
							<td align="center">46</td>
							<td align="center">100</td>
							<td align="center">__</td>
							<td align="center">__</td>
							<td align="center" rowspan="4">0.001<xref ref-type="table-fn"
									rid="TFN04"><sup>a</sup></xref></td>
						</tr>
						<tr>
							<td align="center">25-29</td>
							<td align="center">27</td>
							<td align="center">75</td>
							<td align="center">9</td>
							<td align="center">25</td>
						</tr>
						<tr>
							<td align="center">30-35</td>
							<td align="center">9</td>
							<td align="center">81.8</td>
							<td align="center">2</td>
							<td align="center">18.2</td>
						</tr>
						<tr>
							<td align="center">&gt;35</td>
							<td align="center">__</td>
							<td align="center">__</td>
							<td align="center">3</td>
							<td align="center">100</td>
						</tr>
						<tr>
							<td align="left" rowspan="2">Gender</td>
							<td align="center">Woman</td>
							<td align="center">43</td>
							<td align="center">86</td>
							<td align="center">7</td>
							<td align="center">14</td>
							<td align="center" rowspan="2">0.872<xref ref-type="table-fn"
									rid="TFN05"><sup>b</sup></xref></td>
						</tr>
						<tr>
							<td align="center">Man</td>
							<td align="center">39</td>
							<td align="center">84.8</td>
							<td align="center">7</td>
							<td align="center">15.2</td>
						</tr>
						<tr>
							<td align="left" rowspan="2">Surgical procedure</td>
							<td align="center">MVR</td>
							<td align="center">35</td>
							<td align="center">79.5</td>
							<td align="center">9</td>
							<td align="center">20.5</td>
							<td align="center" rowspan="2">0.137<xref ref-type="table-fn"
									rid="TFN05"><sup>b</sup></xref></td>
						</tr>
						<tr>
							<td align="center">MVR+TDVGA</td>
							<td align="center">47</td>
							<td align="center">90.4</td>
							<td align="center">5</td>
							<td align="center">9.6</td>
						</tr>
						<tr>
							<td align="left" rowspan="2">Previous stroke</td>
							<td align="center">Unavailable</td>
							<td align="center">79</td>
							<td align="center">84.9</td>
							<td align="center">14</td>
							<td align="center">15.1</td>
							<td align="center" rowspan="2">0.472<xref ref-type="table-fn"
									rid="TFN05"><sup>b</sup></xref></td>
						</tr>
						<tr>
							<td align="center">Available</td>
							<td align="center">3</td>
							<td align="center">100</td>
							<td align="center">__</td>
							<td align="center">__</td>
						</tr>
						<tr>
							<td align="left" rowspan="2">Postoperative pacemaker</td>
							<td align="center">Unavailable</td>
							<td align="center">81</td>
							<td align="center">85.3</td>
							<td align="center">14</td>
							<td align="center">14.7</td>
							<td align="center" rowspan="2">0.682<xref ref-type="table-fn"
									rid="TFN05"><sup>b</sup></xref></td>
						</tr>
						<tr>
							<td align="center">Available</td>
							<td align="center">1</td>
							<td align="center">100</td>
							<td align="center">__</td>
							<td align="center">__</td>
						</tr>
						<tr>
							<td align="left" rowspan="2">Chronic obstructive pulmonary disease</td>
							<td align="center">Unavailable</td>
							<td align="center">76</td>
							<td align="center">88.4</td>
							<td align="center">10</td>
							<td align="center">11.6</td>
							<td align="center" rowspan="2">0.016<xref ref-type="table-fn"
									rid="TFN05"><sup>b</sup></xref></td>
						</tr>
						<tr>
							<td align="center">Available</td>
							<td align="center">6</td>
							<td align="center">60</td>
							<td align="center">4</td>
							<td align="center">40</td>
						</tr>
						<tr>
							<td align="left" rowspan="4">New York Heart Association functional
								class</td>
							<td align="center">I</td>
							<td align="center">23</td>
							<td align="center">95.8</td>
							<td align="center">1</td>
							<td align="center">4.2</td>
							<td align="center" rowspan="4">0.343<xref ref-type="table-fn"
									rid="TFN04"><sup>a</sup></xref></td>
						</tr>
						<tr>
							<td align="center">II</td>
							<td align="center">40</td>
							<td align="center">80</td>
							<td align="center">10</td>
							<td align="center">20</td>
						</tr>
						<tr>
							<td align="center">III</td>
							<td align="center">19</td>
							<td align="center">86.4</td>
							<td align="center">3</td>
							<td align="center">13.6</td>
						</tr>
						<tr>
							<td align="center">IV</td>
							<td align="center">__</td>
							<td align="center">__</td>
							<td align="center">__</td>
							<td align="center">__</td>
						</tr>
						<tr>
							<td align="left" rowspan="2">Hypertension</td>
							<td align="center">Unavailable</td>
							<td align="center">74</td>
							<td align="center">91.4</td>
							<td align="center">7</td>
							<td align="center">8.6</td>
							<td align="center" rowspan="2">0.001<xref ref-type="table-fn"
									rid="TFN05"><sup>b</sup></xref></td>
						</tr>
						<tr>
							<td align="center">Available</td>
							<td align="center">8</td>
							<td align="center">53.3</td>
							<td align="center">7</td>
							<td align="center">46.7</td>
						</tr>
						<tr>
							<td align="left" rowspan="2">Ablation type</td>
							<td align="center">RFA</td>
							<td align="center">45</td>
							<td align="center">83.3</td>
							<td align="center">9</td>
							<td align="center">16.7</td>
							<td align="center" rowspan="2">0.517<xref ref-type="table-fn"
									rid="TFN05"><sup>b</sup></xref></td>
						</tr>
						<tr>
							<td align="center">CrA</td>
							<td align="center">37</td>
							<td align="center">88.1</td>
							<td align="center">5</td>
							<td align="center">11.9</td>
						</tr>
						<tr>
							<td align="left" rowspan="3">CRP<xref ref-type="table-fn" rid="TFN05"
										><sup>1</sup></xref> (mg/dL)</td>
							<td align="center">Postoperative</td>
							<td align="center">65.2</td>
							<td align="center">26.4</td>
							<td align="center">84.5</td>
							<td align="center">7.5</td>
							<td align="center">0.266<xref ref-type="table-fn" rid="TFN04"
										><sup>a</sup></xref></td>
						</tr>
						<tr>
							<td align="center">15<sup>th</sup> postoperative day </td>
							<td align="center">9.3</td>
							<td align="center">6.9</td>
							<td align="center">16.4</td>
							<td align="center">8.9</td>
							<td align="center">0.003<xref ref-type="table-fn" rid="TFN04"
										><sup>a</sup></xref></td>
						</tr>
						<tr>
							<td align="center">1<sup>st</sup> postoperative month</td>
							<td align="center">2.7</td>
							<td align="center">1.2</td>
							<td align="center">5.1</td>
							<td align="center">1.0</td>
							<td align="center">0.001<xref ref-type="table-fn" rid="TFN04"
										><sup>a</sup></xref></td>
						</tr>
					</tbody>
				</table>
			</alternatives>
				<table-wrap-foot>
					<fn id="TFN04">
						<label>a</label>
						<p>=independent t test;</p>
					</fn>
					<fn id="TFN05">
						<label>b</label>
						<p>=Chi-square, Fisher's exact test, continuity correction test</p>
					</fn>
					<fn id="TFN06">
						<label>1</label>
						<p>=for statistical analysis of AF recurrence, the data on the same day and
							month were taken into consideration.</p>
					</fn>
					<fn id="TFN07">
						<label><!-- Inserir o valor da label --></label>
						<p>MVR+TDVGA=mitral valve replacement +tricuspid De Vega annuloplasty;
							SD=standard deviation; AF=atrial fibrillation; CrA=cryothermal ablation;
							CRP=C-reactive protein; MVR=mitral valve replacement; RFA=radiofrequency
							ablation</p>
					</fn>
				</table-wrap-foot>
			</table-wrap>
			<p>
				<fig id="f3">
					<label>Fig. 3</label>
					<caption>
						<title>a) Change in the recurrence of AF with left atrium diameter and LVEF.
							b, c, d) Survival analysis of postoperative COPD, BMI and hypertension
							with Mentel-Cox significance values. BMI=body mass index; COPD=chronic
							obstructive pulmonary disease; LA= eft atrium; LVEF=left ventricular
							ejection fraction</title>
					</caption>
					<graphic xlink:href="0102-7638-rbccv-33-06-0542-gf03.jpg"/>
				</fig>
			</p>
			<p>
				<fig id="f4">
					<label>Fig. 4</label>
					<caption>
						<title>The change in CRP levels in relation to the cases with and without AF
							recurrence and the significance ratios according to Cox regression
							analysis. CRP=C-reactive protein</title>
					</caption>
					<graphic xlink:href="0102-7638-rbccv-33-06-0542-gf04.jpg"/>
				</fig>
			</p>
			<p>
				<fig id="f5">
					<label>Fig. 5</label>
					<caption>
						<title>ROC curve analysis graphs of factors affecting AF recurrence.
							AF=atrial fibrillation; BMI=body mass index; LA=left atrium; LVEF=left
							ventricular ejection fraction</title>
					</caption>
					<graphic xlink:href="0102-7638-rbccv-33-06-0542-gf05.jpg"/>
				</fig>
			</p>
			<p>
				<fig id="f6">
					<label>Fig. 6</label>
					<caption>
						<title>Factors correlated with AF recurrence after ablation (r correlation
							coefficient of significance at P&lt;0.05 were taken). AF=atrial
							fibrillation; COPD=chronic obstructive pulmonary disease; CRP=C-reactive
							protein; LA=left atrium; LVEF=left ventricular ejection fraction</title>
					</caption>
					<graphic xlink:href="0102-7638-rbccv-33-06-0542-gf06.jpg"/>
				</fig>
			</p>
			<p>There was a moderate correlation (37.4%) between left atrial diameter and AF
				recurrence (<italic>P</italic>=0.001; r=0.374; <xref ref-type="fig" rid="f3">Figure
					3</xref>). Sensitivity and specificity of left atrial diameter with a cut-off
				value of 50.5 mm for the maintenance of the sinus rhythm were 85.7% and 70.7%,
				respectively (area=0.805; <italic>P</italic>=0.001; 95% CI=0.687-0.923; <xref
					ref-type="fig" rid="f5">Figure 5</xref>).</p>
			<p>The mean preoperative CRP value was 4.5 mg/dL. There was a moderate positive
				correlation between AF recurrence and CRP level on the 15<sup>th</sup> postoperative
				day and at the 1<sup>st</sup> postoperative month (<italic>P</italic>=0.001; r=0.321
				and <italic>P</italic>=0.001; r=0.324, respectively; <xref ref-type="fig" rid="f3"
					>Figure 3D</xref>), whereas no correlation was found between AF recurrence and
				CRP on the 1<sup>st</sup> postoperative day (<italic>P</italic>=0.193; r=0.134). In
				the ROC analysis, the CRP level on the 15<sup>th</sup> postoperative day with a
				cut-off value of 12 mg/dL showed sensitivity of 83.3% and specificity of 88.9%
				(area=0.873; <italic>P</italic>=0.002; 98% CI=0.804-0.942). Sensitivity and
				specificity of CRP level at a cut-off value of 4.5 mg/dL for the maintenance of the
				sinus rhythm at 1<sup>st</sup> postoperative month were 66.7% and 87.8%,
				respectively (area=0.879; <italic>P</italic>=0.046, 95% CI = 0.789-0.968; <xref
					ref-type="table" rid="t1">Table 1</xref>; <xref ref-type="fig" rid="f5">Figure
					5</xref>).</p>
			<p>As BMI values increased, the AF recurrence rate increased significantly. The increase
				in BMI affected AF recurrence by 3.2 times (<italic>P</italic>=0.001; r=0.442; <xref
					ref-type="fig" rid="f3">Figures 3</xref> and <xref ref-type="fig" rid="f5"
					>5</xref>). In cases with BMI&gt;30 kg/m<sup>2</sup> (14.6%; 14 cases),
				recurrent AF frequency (35.7%; 5 cases) was significant (<xref ref-type="table"
					rid="t2">Table 2</xref>). In the ROC analysis, the sensitivity of the BMI at 30
					kg/m<sup>2</sup> cut-off was 35.7%, while the specificity was 89% (area=0.816;
					<italic>P</italic>=0.001; 95% CI=0.720-0.911).</p>
			<p>The mean value of LVEF was 49.3% (35-60%). As LVEF decreased, AF recurrence increased
				(40.1%), indicating a moderate inverse correlation (<italic>P</italic>=0.001;
				r=−0.401). Sensitivity at 37.5% cut-off value of LVEF in ROC analysis was 96.3%,
				while the specificity was 11.4% (area=0.825; <italic>P</italic>=0.001; 95%
				CI=0.711-0.939; <xref ref-type="fig" rid="f3">Figures 3</xref> and <xref
					ref-type="fig" rid="f5">5</xref>).</p>
			<p>It was found that 15.7% of all cases had hypertension. Considering the prevalence of
				hypertension in patients with AF (50%), this ratio was nonspecific in our study,
				which included only valvular patients. AF recurrence was seen in 7 of 15 (46.7%)
				hypertensive patients. Hypertension affected postoperative AF recurrence by 5.3
				times (<italic>P</italic>=0.001; r=0.391; <xref ref-type="fig" rid="f4">Figure
					4</xref>; OR=0.192; 96% CI=0.084-0.453). Patients with COPD accounted for 10.4%
				of our cases. Recurrent AF was observed in 4 (40%) cases with COPD. Low correlation
				with AF recurrence was detected (<italic>P</italic>=0.016; r=0.246; <xref
					ref-type="fig" rid="f5">Figure 5</xref>).</p>
			<p>Postoperative intensive antiarrhythmic therapy was initiated in all cases and
				continued for 3 months. Electrical cardioversion was applied in 3 (3.1%) cases in
				one year. Additional catheter ablation was performed for 2 (14%) of 14 (14.1%)
				patients who developed AF at annual follow-up. No mortality was observed.</p>
		</sec>
		<sec sec-type="discussion">
			<title>DISCUSSION</title>
			<p>From 1987 to 1992, when the Cox maze procedure was reported for the first time,
				continuity of sinus rhythm was reported to be 85-98% in the Cox maze III procedure,
				which was developed through experiments with dog models<sup>[</sup><xref
					ref-type="bibr" rid="B7">7</xref><sup>]</sup>. In a meta-analysis involving six
				studies, the maintenance rate of sinus rhythm in a one-year follow-up of 97 cases
				undergoing mitral valve replacement was reported as being 44% for those undergoing
				concomitant RFA and 4.5% for those without RFA<sup>[</sup><xref ref-type="bibr"
					rid="B8">8</xref><sup>]</sup>. In a meta-analysis involving randomized and
				non-randomized controlled trials, Barnett and Ad<sup>[</sup><xref ref-type="bibr"
					rid="B9">9</xref><sup>]</sup> reported higher rates of sinus rhythm restoration
				(94%) in patients undergoing AF ablation in addition to cardiac surgery than in
				those patients undergoing cardiac surgery alone (4.4%). The limiting characteristic
				of the original cut-and-sew technique was the fear of surgeons arising from the
				complexity of the procedure, as well as the increased possibility of complete
				atrioventricular block and other complications. For this reason, the Cox maze IV
				procedure, which produces transmural lesions with different energy sources, was
				developed. In a study by Lall et al.<sup>[</sup><xref ref-type="bibr" rid="B10"
					>10</xref><sup>]</sup>, maintenance rates of sinus rhythm for one year follow-up
				after Cox maze III and IV procedures were found to be 96% and 93%, respectively. The
				success rate of concomitantly performed AF ablations was 67-84% in retrospective
					reports<sup>[</sup><xref ref-type="bibr" rid="B11">11</xref><sup>]</sup>. The
				variation in the studies was due to different lesion lines, different sources of
				energy, surgeon experience and follow-up strategies. In our study, the maintenance
				rate of sinus rhythm was 85.4% at one-year follow-up. Our results were similar to
				those of the literature. It is understood from the studies performed by McCarthy et
					al.<sup>[</sup><xref ref-type="bibr" rid="B12">12</xref><sup>]</sup> that there
				are significant differences in quality of life among patients with AF who underwent
				simultaneous AF ablation with valve replacement compared with patients who had valve
				replacement without AF ablation.</p>
			<p>Bipolar RFA and CrA are the most frequently recommended techniques for ablation
				during mitral valve replacement<sup>[</sup><xref ref-type="bibr" rid="B13"
					>13</xref><sup>,</sup><xref ref-type="bibr" rid="B14">14</xref><sup>]</sup>.
				Bipolar RFA works according to the principle of lesion formation through a
				transmural hyperthermic heat exchanger clamp in endocardial and epicardial tissues.
				Feedback information on whether these lesions were transmural or not was effective
				in the transition from unipolar to bipolar systems. Bipolar RFA devices have been
				used in our hospital since 2007, but after 2014, nitrous oxide-based CrA devices
				were preferred. Cryotherapy works through the Joule-Thomson effect, cooling the
				tissues. The intracellular ice formation, which can be monitored intraoperatively,
				results in necrosis of the cell<sup>[</sup><xref ref-type="bibr" rid="B13"
					>13</xref><sup>]</sup>. Transmural lesion with CrA was demonstrated
				histologically in experimental sheep models in endocardial and epicardial
					applications<sup>[</sup><xref ref-type="bibr" rid="B14">14</xref><sup>]</sup>.
				It has advantages such as visual confirmation of ice formation, formation of
				progressive transmural lesions, low risk of injury to neighboring tissues and no
				reports of injuries in the valve leaflet, phrenic nerve and coronary arteries
				provided in the literature, even though it is relatively early. The length of the
				application is the disadvantage of CrA, which has been shown to have no effect on
				morbidity and mortality<sup>[</sup><xref ref-type="bibr" rid="B15"
					>15</xref><sup>]</sup>. Brick et al.<sup>[</sup><xref ref-type="bibr" rid="B15"
					>15</xref><sup>]</sup> reported in their meta-analysis of 19 articles that found
				no difference between the one year success rates of sinus rhythm maintaining after
				RFA (67-96%) and CrA (65.5-97.7%). In concomitant interventions, the maintenance
				rate of one year sinus rhythm was 83.3% for bipolar RFA and 88.1% for CrA (<xref
					ref-type="fig" rid="f2">Figure 2</xref>). However, the effect of energy sources
				on AF recurrence was not significant.</p>
			<p>Although Cox maze IV procedure is applicable in both atriums, there are publications
				in recent years reporting that only left atrial ablation could have been
					sufficient<sup>[</sup><xref ref-type="bibr" rid="B16">16</xref><sup>]</sup>. In
				a study by Gillinov et al.<sup>[</sup><xref ref-type="bibr" rid="B17"
					>17</xref><sup>]</sup> comparing biatrial AF ablation with left atrial AF
				ablation, the biatrial ablation technique was significantly superior to the other.
				However, in the studies of Worku et al.<sup>[</sup><xref ref-type="bibr" rid="B18"
					>18</xref><sup>]</sup>, the rate of persistent pacemaker implantation after
				biatrial AF ablation was reported as significantly higher. In 268 cases of biatrial
				cryothermal Cox maze IV procedure performed by Funatsu et al.<sup>[</sup><xref
					ref-type="bibr" rid="B19">19</xref><sup>]</sup>, the rate of sinus rhythm
				restoration in permanent AF was reported to be 80.2%, while the need for permanent
				pacemaker was 8.3%. The need for permanent pacemaker can be explained by the
				preoperative undetected sinus node dysfunction of patients with AF. The incidence of
				pacemaker implantation is also high in the routine follow-up of these
					cases<sup>[</sup><xref ref-type="bibr" rid="B20">20</xref><sup>]</sup>. The fact
				is that surgical ablation performed only in the left atrium may be satisfactory, but
				the increase in flatter incidence from the right atrium after surgery is inevitable.
				For this reason, biatrial ablation should be preferred, especially in cases with a
				history of the atrial flutter<sup>[</sup><xref ref-type="bibr" rid="B19"
					>19</xref><sup>]</sup>. Permanent pacemaker requirement was seen in only one
				(1.8%) of our patients who underwent RFA. Our rate of sinus rhythm per year was
				similar to that of the literature. Our opinion is that it is correct for the surgeon
				to make a case-based decision on the method of ablation.</p>
			<p>Bipolar RFA is not used in minimally invasive procedures because of the difficulties
				encountered in the complete realization of Cox's maze lesions and its ability to
				allow only the pulmonary vein isolation, which we refer to as "box lesions".
				However, CrA is more advantageous in minimally invasive procedures, since the tip of
				the catheter used can be put in any desired shape.</p>
			<p>Analyzes have shown that ablation does not increase operative mortality, and, on the
				contrary, reduces late mortality and morbidity since it reduces postoperative
				thromboembolic risk<sup>[</sup><xref ref-type="bibr" rid="B15"
				>15</xref><sup>]</sup>. Phan et al.<sup>[</sup><xref ref-type="bibr" rid="B20"
					>20</xref><sup>]</sup> found no significant difference in postoperative stroke
				and mortality between two groups of patients, one with concomitant AF ablation and
				the other without it. There was no mortality in our study. One (1.8%) case had a
				stroke in the late period. Gillinov et al.<sup>[</sup><xref ref-type="bibr"
					rid="B17">17</xref><sup>]</sup> reported 3% incidence of stroke for one-year
				follow-up. Our stroke rate was much lower than the risk of AF induced
				thromboembolism (10-20%), even if the risk of valve thrombosis was added. Despite
				the prolonged duration of cardiopulmonary bypass, there was no difference in terms
				of stroke and mortality in the CrA group.</p>
			<p>Complications such as esophageal and coronary arterial damage that occurred in the
				first applications are gradually reduced with the introduction of new energy
					sources<sup>[</sup><xref ref-type="bibr" rid="B21">21</xref><sup>]</sup>. In a
				published report of esophageal perforations after surgical AF ablation, 26 of 29
				cases of esophageal perforation were reported to have occurred after RFA and one
				case after CrA<sup>[</sup><xref ref-type="bibr" rid="B21">21</xref><sup>]</sup>. No
				esophageal perforation was detected in our cases. In only one case, there was
				minimal damage to the posterior wall of the left atrium after bipolar RFA. The
				damage was repaired without additional complications.</p>
			<p>It is not sufficient to use only intermittent ECG records in the long-term follow-up
				of patients with restored sinus rhythm due of the possibility that rhythm is caught
				in a short and transient period of sinus node activity, and thus, a paroxysmal
				atrial arrhythmia may go unnoticed. For this reason, we think that it is best to use
				a 24-hour Holter ECG or rhythm monitor, especially in the early period. In our
				cases, we performed Holter monitoring every 6 months. Continuous ECG monitoring was
				performed in cases with recurrent AF. Therapeutic modalities such as antiarrhythmic
				therapy and cardioversion were applied in the recurrent AF cases detected at 12
				months of follow-up.</p>
			<p>After the operation, amiodarone and nonsteroidal anti-inflammatory drug therapy were
				applied for 3 months, considering the catecholamine increase and metabolic inducers.
				The first 3 months after ablation are called the "blind period". In this period,
				antiarrhythmics may prevent early AF recurrence triggered by ablated tissue-derived
				rhythm disorders (proarrhythmias)<sup>[</sup><xref ref-type="bibr" rid="B22"
					>22</xref><sup>]</sup>. Amiodarone also provides rate control against
				arrhythmia.</p>
			<p>Restoration of sinus rhythm after ablation is an independent predictor of successful
				ablation in the 12<sup>th</sup> postoperative month. Damiano et al.<sup>[</sup><xref
					ref-type="bibr" rid="B23">23</xref><sup>]</sup> found high rates of AF
				recurrence at a 12<sup>th</sup> postoperative month in patients with atrial
				tachycardia in the early postoperative period. AF recurrence was observed in 6 of 14
				(42.9%) cases in the first 15 days (<xref ref-type="fig" rid="f2">Figure 2</xref>).
				We think that early AF recurrence is caused by the intense effect of proarrhythmic
				factors.</p>
			<p>Since the early 2000's, researchers have argued that AF is caused by inflammatory
				processes. The study results have shown that there is a correlation between CRP and
					inflammation<sup>[</sup><xref ref-type="bibr" rid="B24">24</xref><sup>]</sup>.
				However, the effect of inflammation on the left atrium size and the pathogenesis of
				the dysrhythmias is controversial. Psychari et al.<sup>[</sup><xref ref-type="bibr"
					rid="B24">24</xref><sup>]</sup> found a significant association between AF
				occurrence and CRP and interleukin-6 levels in their study of 90 patients. In their
				study of 50 patients with and without persistent AF, Watanabe et
					al.<sup>[</sup><xref ref-type="bibr" rid="B25">25</xref><sup>]</sup> reported
				that the left ventricular mass and increased left ventricular end-diastolic diameter
				were determinants of CRP elevation and AF persistence. In our study, CRP levels were
				found to be high but not significant on the 1<sup>st</sup> postoperative day. On the
					15<sup>th</sup> postoperative day, the sensitivity and specificity of CRP in
				terms of effect on AF recurrence with a cut-off value of 12 mg/dL were found to be
				83.3% and 88.9%, respectively (area=0.873; <italic>P</italic>=0.002; 98%
				CI=0.804-0.942; <xref ref-type="fig" rid="f2">Figures 2</xref>-<xref ref-type="fig"
					rid="f4">4</xref>). The sensitivity and specificity ratios at 1<sup>st</sup>
				postoperative month for CRP with a cut-off value of 4.5 mg/dL were 66.7% and 87.8%,
				respectively (area=0.879; P=0.046; 95% CI=0.789-0.968; <xref ref-type="table"
					rid="t1">Table 1</xref>). The effect of energy sources on postoperative CRP
				level was not significant (<italic>P</italic>&gt;0.05; <xref ref-type="table"
					rid="t1">Table 1</xref>).</p>
			<p>Funatsu et al.<sup>[</sup><xref ref-type="bibr" rid="B19">19</xref><sup>]</sup>
				reported that AF recurrence rate after ablation was increased when the left atrium
				size was &#x2265;70 mm and AF had been present over 10 years. Some studies have
				reported that left atrium diameter greater than 60 mm and the presence of
				hypertension are independent risk factors for unsuccessful ablation<sup>[</sup><xref
					ref-type="bibr" rid="B23">23</xref><sup>]</sup>. Although the effect of left
				atrium diameter on primary AF is supported, there is insufficient data on whether
				left atrium diameter after ablation is a predictor for AF recurrence. In our study,
				sensitivity and specificity ratios of left atrium diameter for AF recurrence with a
				cut-off value of 50.5 mm were 85.7% and 70.7%, respectively. Left atrium diameter
				was greater than 50.5 mm in 12 (85.7%) of the 14 patients with recurrent AF. Our
				results are similar to those of Chavez et al.<sup>[</sup><xref ref-type="bibr"
					rid="B11">11</xref><sup>]</sup>.</p>
			<p>Ducceschi et al.<sup>[</sup><xref ref-type="bibr" rid="B26">26</xref><sup>]</sup>
				reported that, in a series of 150 cases (BMI &gt;30 kg/m<sup>2</sup>), AF was more
				common in obese patients. Adipose tissue is an active endocrine organ that secretes
				many hormones and cytokines (TNF-&#x03b1;, IL-6, IL-8), such as leptin, resistin and
				adiponectin. These cytokines lead to systemic inflammation and affect insulin
				resistance and pulmonary function<sup>[</sup><xref ref-type="bibr" rid="B24"
					>24</xref><sup>]</sup>. This causes left atrium growth and contributes to
				irregularity in electrolyte metabolism. Recurrent AF was more frequent in our cases
				with postoperative BMI &gt;30 kg/m<sup>2</sup> (14 cases) and the difference was
				significant (<xref ref-type="table" rid="t2">Table 2</xref>; <xref ref-type="fig"
					rid="f3">Figures 3</xref> to <xref ref-type="fig" rid="f6">6</xref>).
				Sensitivity and specificity of obesity were 35.7% and 89%, respectively, in terms of
				AF recurrence with a cut-off value of 30 kg m<sup>2</sup> (area=0.816;
					<italic>P</italic>=0.001; 95% CI=0.720-0.911). The increase in BMI affected AF
				recurrence by 3.2-fold.</p>
			<p>The prevalence of hypertension in developed countries is around
					25-30%<sup>[</sup><xref ref-type="bibr" rid="B27">27</xref><sup>]</sup>. Cohort
				studies showed the presence of hypertension in 53% of patients with AF and a causal
				linkage in 15% of patients with AF<sup>[</sup><xref ref-type="bibr" rid="B27"
					>27</xref><sup>]</sup>. In our cases, there were sufficient reasons for the
				development of AF, but 15 patients were being treated for hypertension at the same
				time (<xref ref-type="table" rid="t1">Table 1</xref>). Recurrence of postoperative
				AF was seen in 7 (46.7%) cases with hypertension. The recurrence of AF was 5.3 times
				more frequent in hypertensive cases when compared to non-hypertensive cases.</p>
			<p>Our experience and the studies reported in the literature have shown that successful
				results are obtained if AF ablation is carried out during cardiac surgery. Although
				there are no clear criteria for patient selection, cases with left atrial diameter
				&#x2265;50 mm, LVEF &#x2264; 37%, and heart failure of NYHA class III-IV should be
				excluded. Nevertheless, in the American College of Cardiology (ACC)/AHA and European
				Society of Cardiology (ESC)/EHRA guidelines<sup>[</sup><xref ref-type="bibr"
					rid="B4">4</xref><sup>]</sup>, AF ablation is recommended with a low level of
				evidence (Class 2b) for cases with medical treatment refractory to symptomatic heart
				failure and/or atrial enlargement. In our cases, LVEF presented 96.3% sensitivity
				and 11.4% specificity with a cut-off value of 37.5% (area=0.825;
				<italic>P</italic>=0.001; 95% CI 0.711-0.939; <xref ref-type="fig" rid="f3">Figures
					3</xref> and <xref ref-type="fig" rid="f5">5</xref>).</p>
			<sec>
				<title>Limitation</title>
				<p>Detection of recurrent AF in a longer period may not be possible, since our
					follow-up period has been limited to 1 year. For this reason, we realize that
					the most valuable results for the comparison of different energy sources used in
					Cox maze IV procedure will come from large series with long-term follow-up.</p>
				<p>In our single-center nonrandomized trial, it was not possible to eliminate the
					confounding variables that affect AF recurrence. For this reason, our 1-year
					follow-up was influenced by factors other than energy sources. However, it is
					understood from the demographic data that the confounding factors that we have
					detected do not display nonuniform distribution among the groups (<xref
						ref-type="table" rid="t1">Table 1</xref>).</p>
			</sec>
		</sec>
		<sec sec-type="conclusions">
			<title>CONCLUSION</title>
			<p>Considering the high incidence and complication rate, persistent AF requires
				aggressive treatment and follow-up, we believe that it is necessary to perform AF
				ablation in case of necessity in all cases where cardiac surgery is planned. In our
				cases with bipolar RFA and CrA, we found acceptable rates of AF recurrence,
				mortality and stroke at one-year follow-up. Even if there is no difference between
				the efficiency of the energy systems we used, an increase in the demand for
				alternative systems will occur in a world moving toward less invasive procedures. We
				believe that controlling risk factors and following appropriate medical procedures
				are as effective as surgical procedure and energy source on sinus rhythm
				maintenance. However, we believe that if cardiologists and surgeons interested in
				electrophysiology work together with a multidisciplinary team approach in choosing
				the right patient and procedure, success rate first and then quality of life will
				increase.</p>
			<table-wrap id="t4">
						<alternatives>
							<graphic xlink:href="t3.jpg"/>
				<table frame="hsides" rules="groups">
					<colgroup>
						<col width="5%"/>
						<col width="95%"/>
					</colgroup>
					<thead>
						<tr>
							<th align="left" colspan="2"><bold>Authors’ roles &amp;
									responsibilities</bold></th>
						</tr>
					</thead>
					<tbody>
						<tr>
							<td align="left">ÜV</td>
							<td align="left">Substantial contributions to the conception or design
								of the work; or the acquisition, analysis, or interpretation of data
								for the work; drafting the work or revising it critically for
								important intellectual content; agreement to be accountable for all
								aspects of the work in ensuring that questions related to the
								accuracy or integrity of any part of the work are appropriately
								investigated and resolved; final approval of the version to be
								published</td>
						</tr>
						<tr>
							<td align="left">AYB</td>
							<td align="left">Final approval of the version to be published</td>
						</tr>
						<tr>
							<td align="left">AAA</td>
							<td align="left">Agreement to be accountable for all aspects of the work
								in ensuring that questions related to the accuracy or integrity of
								any part of the work are appropriately investigated and resolved;
								final approval of the version to be published</td>
						</tr>
						<tr>
							<td align="left">MK</td>
							<td align="left">Drafting the work or revising it critically for
								important intellectual content; final approval of the version to be
								published</td>
						</tr>
					</tbody>
				</table>
			</alternatives>
			</table-wrap>
		</sec>
	</body>
	<back>
		<fn-group>
			<fn fn-type="other">
				<p>This study was carried out at Dr. Siyami Ersek Thoracic and Cardiovascular
					Surgery Training and Research Hospital, Istanbul, Turkey.</p>
			</fn>
			<fn fn-type="supported-by">
				<p>No financial support.</p>
			</fn>
		</fn-group>
		<ref-list>
			<title>REFERENCES</title>
			<ref id="B1">
				<label>1</label>
				<mixed-citation>Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et
					al; ESC Committee for Practice Guidelines. Guidelines for the management of
					atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of
					the European Society of Cardiology (ESC). Europace.
					2010;12(10):1360-420.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Camm</surname>
							<given-names>AJ</given-names>
						</name>
						<name>
							<surname>Kirchhof</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Lip</surname>
							<given-names>GY</given-names>
						</name>
						<name>
							<surname>Schotten</surname>
							<given-names>U</given-names>
						</name>
						<name>
							<surname>Savelieva</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Ernst</surname>
							<given-names>S</given-names>
						</name>
						<etal/>
						<collab>ESC Committee for Practice Guidelines</collab>
					</person-group>
					<article-title>Guidelines for the management of atrial fibrillation: the Task
						Force for the Management of Atrial Fibrillation of the European Society of
						Cardiology (ESC)</article-title>
					<source>Europace</source>
					<year>2010</year>
					<volume>12</volume>
					<issue>10</issue>
					<fpage>1360</fpage>
					<lpage>1420</lpage>
				</element-citation>
			</ref>
			<ref id="B2">
				<label>2</label>
				<mixed-citation>Fornari LS, Calderaro D, Nassar IB, Lauretti C, Nakamura L,
					Bagnatori R, et al. Misuse of antithrombotic therapy in atrial fibrillation
					patients: frequent, pervasive and persistent. J Thromb Thrombolysis.
					2007;23(1):65-71.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Fornari</surname>
							<given-names>LS</given-names>
						</name>
						<name>
							<surname>Calderaro</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Nassar</surname>
							<given-names>IB</given-names>
						</name>
						<name>
							<surname>Lauretti</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Nakamura</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Bagnatori</surname>
							<given-names>R</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Misuse of antithrombotic therapy in atrial fibrillation patients:
						frequent, pervasive and persistent</article-title>
					<source>J Thromb Thrombolysis</source>
					<year>2007</year>
					<volume>23</volume>
					<issue>1</issue>
					<fpage>65</fpage>
					<lpage>71</lpage>
				</element-citation>
			</ref>
			<ref id="B3">
				<label>3</label>
				<mixed-citation>Adalet K. The surgical treatment of atrial fibrillation. Türk
					Kardiyol Dern Arfl. 2002;30:104-18.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Adalet</surname>
							<given-names>K</given-names>
						</name>
					</person-group>
					<article-title>The surgical treatment of atrial fibrillation</article-title>
					<source>Türk Kardiyol Dern Arfl</source>
					<year>2002</year>
					<volume>30</volume>
					<fpage>104</fpage>
					<lpage>118</lpage>
				</element-citation>
			</ref>
			<ref id="B4">
				<label>4</label>
				<mixed-citation>Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al;
					Heart Rhythm Society Task Force on Catheter and Surgical Ablation of Atrial
					Fibrillation. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and
					surgical ablation of atrial fibrillation: recommendations for patient selection,
					procedural techniques, patient management and follow-up, definitions, endpoints,
					and research trial design: a report of the Heart Rhythm Society (HRS) Task Force
					on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in
					partnership with the European Heart Rhythm Association (EHRA), a registered
					branch of the European Society of Cardiology (ESC) and the European Cardiac
					Arrhythmia Society (ECAS); and in collaboration with the American College of
					Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart
					Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by
					the governing bodies of the American College of Cardiology Foundation, the
					American Heart Association, the European Cardiac Arrhythmia Society, the
					European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia
					Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm.
					2012;9(4):632-96.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Calkins</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Kuck</surname>
							<given-names>KH</given-names>
						</name>
						<name>
							<surname>Cappato</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Brugada</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Camm</surname>
							<given-names>AJ</given-names>
						</name>
						<name>
							<surname>Chen</surname>
							<given-names>SA</given-names>
						</name>
						<etal/>
						<collab>Heart Rhythm Society Task Force on Catheter and Surgical Ablation of
							Atrial Fibrillation</collab>
					</person-group>
					<article-title>2012 HRS/EHRA/ECAS expert consensus statement on catheter and
						surgical ablation of atrial fibrillation: recommendations for patient
						selection, procedural techniques, patient management and follow-up,
						definitions, endpoints, and research trial design: a report of the Heart
						Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial
						Fibrillation. Developed in partnership with the European Heart Rhythm
						Association (EHRA), a registered branch of the European Society of
						Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in
						collaboration with the American College of Cardiology (ACC), American Heart
						Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the
						Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the
						American College of Cardiology Foundation, the American Heart Association,
						the European Cardiac Arrhythmia Society, the European Heart Rhythm
						Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm
						Society, and the Heart Rhythm Society</article-title>
					<source>Heart Rhythm</source>
					<year>2012</year>
					<volume>9</volume>
					<issue>4</issue>
					<fpage>632</fpage>
					<lpage>696</lpage>
				</element-citation>
			</ref>
			<ref id="B5">
				<label>5</label>
				<mixed-citation>Gammie JS, Haddad M, Milford-Beland S, Welke KF, Ferguson TB Jr,
					O'Brien SM, et al. Atrial fibrillation correction surgery: lessons from the
					Society of Thoracic Surgeons National Cardiac Database. Ann Thorac Surg.
					2008;85(3):909-14.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gammie</surname>
							<given-names>JS</given-names>
						</name>
						<name>
							<surname>Haddad</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Milford-Beland</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Welke</surname>
							<given-names>KF</given-names>
						</name>
						<name>
							<surname>Ferguson</surname>
							<given-names>TB</given-names>
							<suffix>Jr</suffix>
						</name>
						<name>
							<surname>O'Brien</surname>
							<given-names>SM</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Atrial fibrillation correction surgery: lessons from the Society
						of Thoracic Surgeons National Cardiac Database</article-title>
					<source>Ann Thorac Surg</source>
					<year>2008</year>
					<volume>85</volume>
					<issue>3</issue>
					<fpage>909</fpage>
					<lpage>914</lpage>
				</element-citation>
			</ref>
			<ref id="B6">
				<label>6</label>
				<mixed-citation>Gillinov AM, Sirak J, Blackstone EH, McCarthy PM, Rajeswaran J,
					Pettersson G, et al. The Cox maze procedure in mitral valve disease: predictors
					of recurrent atrial fibrillation. J Thorac Cardiovasc Surg.
					2005;130(6):1653-60.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gillinov</surname>
							<given-names>AM</given-names>
						</name>
						<name>
							<surname>Sirak</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Blackstone</surname>
							<given-names>EH</given-names>
						</name>
						<name>
							<surname>McCarthy</surname>
							<given-names>PM</given-names>
						</name>
						<name>
							<surname>Rajeswaran</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Pettersson</surname>
							<given-names>G</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>The Cox maze procedure in mitral valve disease: predictors of
						recurrent atrial fibrillation</article-title>
					<source>J Thorac Cardiovasc Surg</source>
					<year>2005</year>
					<volume>130</volume>
					<issue>6</issue>
					<fpage>1653</fpage>
					<lpage>1660</lpage>
				</element-citation>
			</ref>
			<ref id="B7">
				<label>7</label>
				<mixed-citation>Cox JL, Ad N, Palazzo T, Fitzpatrick S, Suyderhoud JP, DeGroot KW,
					et al. Current status of the Maze procedure for the treatment of atrial
					fibrillation. Semin Thorac Cardiovasc Surg. 2000;12(1):15-9.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Cox</surname>
							<given-names>JL</given-names>
						</name>
						<name>
							<surname>Ad</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Palazzo</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Fitzpatrick</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Suyderhoud</surname>
							<given-names>JP</given-names>
						</name>
						<name>
							<surname>DeGroot</surname>
							<given-names>KW</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Current status of the Maze procedure for the treatment of atrial
						fibrillation</article-title>
					<source>Semin Thorac Cardiovasc Surg</source>
					<year>2000</year>
					<volume>12</volume>
					<issue>1</issue>
					<fpage>15</fpage>
					<lpage>19</lpage>
				</element-citation>
			</ref>
			<ref id="B8">
				<label>8</label>
				<mixed-citation>Doukas G, Samani NJ, Alexiou C, Oc M, Chin DT, Stafford PG, et al.
					Left atrial radiofrequency ablation during mitral valve surgery for continuous
					atrial fibrillation: a randomized controlled trial. JAMA.
					2005;294(18):2323-9.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Doukas</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Samani</surname>
							<given-names>NJ</given-names>
						</name>
						<name>
							<surname>Alexiou</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Oc</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Chin</surname>
							<given-names>DT</given-names>
						</name>
						<name>
							<surname>Stafford</surname>
							<given-names>PG</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Left atrial radiofrequency ablation during mitral valve surgery
						for continuous atrial fibrillation: a randomized controlled
						trial</article-title>
					<source>JAMA</source>
					<year>2005</year>
					<volume>294</volume>
					<issue>18</issue>
					<fpage>2323</fpage>
					<lpage>2329</lpage>
				</element-citation>
			</ref>
			<ref id="B9">
				<label>9</label>
				<mixed-citation>Barnett SD, Ad N. Surgical ablation as treatment for the elimination
					of atrial fibrillation: a meta-analysis. J Thorac Cardiovasc Surg.
					2006;131(5):1029-35.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Barnett</surname>
							<given-names>SD</given-names>
						</name>
						<name>
							<surname>Ad</surname>
							<given-names>N</given-names>
						</name>
					</person-group>
					<article-title>Surgical ablation as treatment for the elimination of atrial
						fibrillation: a meta-analysis</article-title>
					<source>J Thorac Cardiovasc Surg</source>
					<year>2006</year>
					<volume>131</volume>
					<issue>5</issue>
					<fpage>1029</fpage>
					<lpage>1035</lpage>
				</element-citation>
			</ref>
			<ref id="B10">
				<label>10</label>
				<mixed-citation>Lall SC, Melby SJ, Voeller RK, Zierer A, Bailey MS, Guthrie TJ, et
					al. The effect of ablation technology on surgical outcomes after the Cox-maze
					procedure: a propensity analysis. J Thorac Cardiovasc Surg.
					2007;133(2):389-96.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Lall</surname>
							<given-names>SC</given-names>
						</name>
						<name>
							<surname>Melby</surname>
							<given-names>SJ</given-names>
						</name>
						<name>
							<surname>Voeller</surname>
							<given-names>RK</given-names>
						</name>
						<name>
							<surname>Zierer</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Bailey</surname>
							<given-names>MS</given-names>
						</name>
						<name>
							<surname>Guthrie</surname>
							<given-names>TJ</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>The effect of ablation technology on surgical outcomes after the
						Cox-maze procedure: a propensity analysis</article-title>
					<source>J Thorac Cardiovasc Surg</source>
					<year>2007</year>
					<volume>133</volume>
					<issue>2</issue>
					<fpage>389</fpage>
					<lpage>396</lpage>
				</element-citation>
			</ref>
			<ref id="B11">
				<label>11</label>
				<mixed-citation>Chavez EK, Colafranceschi AS, Monteiro AJO, Canale SC, Mesquita ET,
					Weksler C, et al. Surgical treatment of atrial fibrillation in patients with
					rheumatic valve disease. Braz J Cardiovasc Surg.
					2017;32(3):202-9.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Chavez</surname>
							<given-names>EK</given-names>
						</name>
						<name>
							<surname>Colafranceschi</surname>
							<given-names>AS</given-names>
						</name>
						<name>
							<surname>Monteiro</surname>
							<given-names>AJO</given-names>
						</name>
						<name>
							<surname>Canale</surname>
							<given-names>SC</given-names>
						</name>
						<name>
							<surname>Mesquita</surname>
							<given-names>ET</given-names>
						</name>
						<name>
							<surname>Weksler</surname>
							<given-names>C</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Surgical treatment of atrial fibrillation in patients with
						rheumatic valve disease</article-title>
					<source>Braz J Cardiovasc Surg</source>
					<year>2017</year>
					<volume>32</volume>
					<issue>3</issue>
					<fpage>202</fpage>
					<lpage>209</lpage>
				</element-citation>
			</ref>
			<ref id="B12">
				<label>12</label>
				<mixed-citation>McCarthy PM, Manjunath A, Kruse J, Andrei AC, Li Z, McGee EC Jr, et
					al. Should paroxysmal atrial fibrillation be treated during cardiac surgery? J
					Thorac Cardiovasc Surg. 2013;146(4):810-23.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>McCarthy</surname>
							<given-names>PM</given-names>
						</name>
						<name>
							<surname>Manjunath</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Kruse</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Andrei</surname>
							<given-names>AC</given-names>
						</name>
						<name>
							<surname>Li</surname>
							<given-names>Z</given-names>
						</name>
						<name>
							<surname>McGee</surname>
							<given-names>EC</given-names>
							<suffix>Jr</suffix>
						</name>
						<etal/>
					</person-group>
					<article-title>Should paroxysmal atrial fibrillation be treated during cardiac
						surgery?</article-title>
					<source>J Thorac Cardiovasc Surg</source>
					<year>2013</year>
					<volume>146</volume>
					<issue>4</issue>
					<fpage>810</fpage>
					<lpage>823</lpage>
				</element-citation>
			</ref>
			<ref id="B13">
				<label>13</label>
				<mixed-citation>Gage AA, Baust J. Mechanism of tissue injury in cryosurgery.
					Cryobiology. 1998;37(3):171-86.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gage</surname>
							<given-names>AA</given-names>
						</name>
						<name>
							<surname>Baust</surname>
							<given-names>J</given-names>
						</name>
					</person-group>
					<article-title>Mechanism of tissue injury in cryosurgery</article-title>
					<source>Cryobiology</source>
					<year>1998</year>
					<volume>37</volume>
					<issue>3</issue>
					<fpage>171</fpage>
					<lpage>186</lpage>
				</element-citation>
			</ref>
			<ref id="B14">
				<label>14</label>
				<mixed-citation>Gallegos RP, Rivard AL, Rajab TK, Schmitto JD, Lahti MT, Kirchhof N,
					et al. Transmural atrial fibrosis after epicardial and endocardial argon-powered
					CryoMaze ablation. J Card Surg. 2011;26(2):240-3.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gallegos</surname>
							<given-names>RP</given-names>
						</name>
						<name>
							<surname>Rivard</surname>
							<given-names>AL</given-names>
						</name>
						<name>
							<surname>Rajab</surname>
							<given-names>TK</given-names>
						</name>
						<name>
							<surname>Schmitto</surname>
							<given-names>JD</given-names>
						</name>
						<name>
							<surname>Lahti</surname>
							<given-names>MT</given-names>
						</name>
						<name>
							<surname>Kirchhof</surname>
							<given-names>N</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Transmural atrial fibrosis after epicardial and endocardial
						argon-powered CryoMaze ablation</article-title>
					<source>J Card Surg</source>
					<year>2011</year>
					<volume>26</volume>
					<issue>2</issue>
					<fpage>240</fpage>
					<lpage>243</lpage>
				</element-citation>
			</ref>
			<ref id="B15">
				<label>15</label>
				<mixed-citation>Brick AV, Braile DM, Surgical ablation of atrial fibrillation using
					energy sources. Braz J Cardiovasc Surg. 2015;30(6):636-43.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Brick</surname>
							<given-names>AV</given-names>
						</name>
						<name>
							<surname>Braile</surname>
							<given-names>DM</given-names>
						</name>
					</person-group>
					<article-title>Surgical ablation of atrial fibrillation using energy
						sources</article-title>
					<source>Braz J Cardiovasc Surg</source>
					<year>2015</year>
					<volume>30</volume>
					<issue>6</issue>
					<fpage>636</fpage>
					<lpage>643</lpage>
				</element-citation>
			</ref>
			<ref id="B16">
				<label>16</label>
				<mixed-citation>Khargi K, Deneke T, Lemke B, Laczkovics A. Irrigated radiofrequency
					ablation is a safe and effective technique to treat chronic atrial fibrillation.
					Interact Cardiovasc Thorac Surg. 2003;2(3):241-5.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Khargi</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Deneke</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Lemke</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Laczkovics</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>Irrigated radiofrequency ablation is a safe and effective
						technique to treat chronic atrial fibrillation</article-title>
					<source>Interact Cardiovasc Thorac Surg</source>
					<year>2003</year>
					<volume>2</volume>
					<issue>3</issue>
					<fpage>241</fpage>
					<lpage>245</lpage>
				</element-citation>
			</ref>
			<ref id="B17">
				<label>17</label>
				<mixed-citation>Gillinov AM, Gelijns AC, Parides MK, DeRose JJ Jr, Moskowitz AJ,
					Voisine P, et al; CTSN Investigators. Surgical ablation of atrial fibrillation
					during mitral-valve surgery. N Engl J Med.
					2015;372(15):1399-409.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gillinov</surname>
							<given-names>AM</given-names>
						</name>
						<name>
							<surname>Gelijns</surname>
							<given-names>AC</given-names>
						</name>
						<name>
							<surname>Parides</surname>
							<given-names>MK</given-names>
						</name>
						<name>
							<surname>DeRose</surname>
							<given-names>JJ</given-names>
							<suffix>Jr</suffix>
						</name>
						<name>
							<surname>Moskowitz</surname>
							<given-names>AJ</given-names>
						</name>
						<name>
							<surname>Voisine</surname>
							<given-names>P</given-names>
						</name>
						<etal/>
						<collab>CTSN Investigators</collab>
					</person-group>
					<article-title>Surgical ablation of atrial fibrillation during mitral-valve
						surgery</article-title>
					<source>N Engl J Med</source>
					<year>2015</year>
					<volume>372</volume>
					<issue>15</issue>
					<fpage>1399</fpage>
					<lpage>1409</lpage>
				</element-citation>
			</ref>
			<ref id="B18">
				<label>18</label>
				<mixed-citation>Worku B, Pak SW, Cheema F, Russo M, Housman B, Van Patten D, et al.
					Incidence and predictors of pacemaker placement after surgical ablation for
					atrial fibrillation. Ann Thorac Surg. 2011;92(6):2085-9.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Worku</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Pak</surname>
							<given-names>SW</given-names>
						</name>
						<name>
							<surname>Cheema</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Russo</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Housman</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Van Patten</surname>
							<given-names>D</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Incidence and predictors of pacemaker placement after surgical
						ablation for atrial fibrillation</article-title>
					<source>Ann Thorac Surg</source>
					<year>2011</year>
					<volume>92</volume>
					<issue>6</issue>
					<fpage>2085</fpage>
					<lpage>2089</lpage>
				</element-citation>
			</ref>
			<ref id="B19">
				<label>19</label>
				<mixed-citation>Funatsu T, Kobayashi J, Nakajima H, Iba Y, Shimahara Y, Yagihara T.
					Long-term results and reliability of cryothermic ablation based maze procedure
					for atrial fibrillation concomitant with mitral valve surgery. Eur J
					Cardiothorac Surg. 2009;36(2):267-71.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Funatsu</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Kobayashi</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Nakajima</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Iba</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Shimahara</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Yagihara</surname>
							<given-names>T</given-names>
						</name>
					</person-group>
					<article-title>Long-term results and reliability of cryothermic ablation based
						maze procedure for atrial fibrillation concomitant with mitral valve
						surgery</article-title>
					<source>Eur J Cardiothorac Surg</source>
					<year>2009</year>
					<volume>36</volume>
					<issue>2</issue>
					<fpage>267</fpage>
					<lpage>271</lpage>
				</element-citation>
			</ref>
			<ref id="B20">
				<label>20</label>
				<mixed-citation>Phan K, Xie A, La Meir M, Black D, Yan T. Surgical ablation for
					treatment of atrial fibrillation in cardiac surgery: a cumulative meta-analysis
					of randomized controlled trials. Heart. 2014;100(9):722-30.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Phan</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Xie</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>La Meir</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Black</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Yan</surname>
							<given-names>T</given-names>
						</name>
					</person-group>
					<article-title>Surgical ablation for treatment of atrial fibrillation in cardiac
						surgery: a cumulative meta-analysis of randomized controlled
						trials</article-title>
					<source>Heart</source>
					<year>2014</year>
					<volume>100</volume>
					<issue>9</issue>
					<fpage>722</fpage>
					<lpage>730</lpage>
				</element-citation>
			</ref>
			<ref id="B21">
				<label>21</label>
				<mixed-citation>Singh SM, d'Avila A, Singh SK, Stelzer P, Saad EB, Skanes A, et al.
					Clinical outcomes after repair of left atrial-esophageal fistulas occurring
					after atrial fibrillation ablation procedures Heart Rhythm.
					2013;10(11):1591-7.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Singh</surname>
							<given-names>SM</given-names>
						</name>
						<name>
							<surname>d'Avila</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Singh</surname>
							<given-names>SK</given-names>
						</name>
						<name>
							<surname>Stelzer</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Saad</surname>
							<given-names>EB</given-names>
						</name>
						<name>
							<surname>Skanes</surname>
							<given-names>A</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Clinical outcomes after repair of left atrial-esophageal fistulas
						occurring after atrial fibrillation ablation procedures
						Heart</article-title>
					<source>Rhythm</source>
					<year>2013</year>
					<volume>10</volume>
					<issue>11</issue>
					<fpage>1591</fpage>
					<lpage>1597</lpage>
				</element-citation>
			</ref>
			<ref id="B22">
				<label>22</label>
				<mixed-citation>Cosedis Nielsen J, Johannessen A, Raatikainen P, Hindricks G,
					Walfridsson H, Kongstad O, et al. Radiofrequency ablation as initial therapy in
					paroxysmal atrial fibrillation. N Engl J Med.
					2012;367(17):1587-95.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Cosedis Nielsen</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Johannessen</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Raatikainen</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Hindricks</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Walfridsson</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Kongstad</surname>
							<given-names>O</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Radiofrequency ablation as initial therapy in paroxysmal atrial
						fibrillation</article-title>
					<source>N Engl J Med</source>
					<year>2012</year>
					<volume>367</volume>
					<issue>17</issue>
					<fpage>1587</fpage>
					<lpage>1595</lpage>
				</element-citation>
			</ref>
			<ref id="B23">
				<label>23</label>
				<mixed-citation>Damiano RJ Jr, Schwartz FH, Bailey MS, Maniar HS, Munfakh NA, Moon
					MR, et al. The Cox maze IV procedure: predictors of late recurrence. J Thorac
					Cardiovasc Surg. 2011;141(1):113-21.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Damiano</surname>
							<given-names>RJ</given-names>
							<suffix>Jr</suffix>
						</name>
						<name>
							<surname>Schwartz</surname>
							<given-names>FH</given-names>
						</name>
						<name>
							<surname>Bailey</surname>
							<given-names>MS</given-names>
						</name>
						<name>
							<surname>Maniar</surname>
							<given-names>HS</given-names>
						</name>
						<name>
							<surname>Munfakh</surname>
							<given-names>NA</given-names>
						</name>
						<name>
							<surname>Moon</surname>
							<given-names>MR</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>The Cox maze IV procedure: predictors of late
						recurrence</article-title>
					<source>J Thorac Cardiovasc Surg</source>
					<year>2011</year>
					<volume>141</volume>
					<issue>1</issue>
					<fpage>113</fpage>
					<lpage>121</lpage>
				</element-citation>
			</ref>
			<ref id="B24">
				<label>24</label>
				<mixed-citation>Psychari SN, Apostolou TS, Santos L, Hamodraka E, Liakos G,
					Kremastinos DT. Relation of elevated C-reactive protein and interleukin-6 levels
					to left atrial size and duration of episodes in patients with atrial
					fibrillation. Am J Cardiol. 2005;95(6):764-7.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Psychari</surname>
							<given-names>SN</given-names>
						</name>
						<name>
							<surname>Apostolou</surname>
							<given-names>TS</given-names>
						</name>
						<name>
							<surname>Santos</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Hamodraka</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Liakos</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Kremastinos</surname>
							<given-names>DT</given-names>
						</name>
					</person-group>
					<article-title>Relation of elevated C-reactive protein and interleukin-6 levels
						to left atrial size and duration of episodes in patients with atrial
						fibrillation</article-title>
					<source>Am J Cardiol</source>
					<year>2005</year>
					<volume>95</volume>
					<issue>6</issue>
					<fpage>764</fpage>
					<lpage>767</lpage>
				</element-citation>
			</ref>
			<ref id="B25">
				<label>25</label>
				<mixed-citation>Watanabe T, Takeishi Y, Hirono O, Itoh M, Matsui M, Nakamura K, et
					al. C-reactive protein elevation predicts the occurrence of atrial structural
					remodeling in patients with paroxysmal atrial fibrillation. Heart Vessels.
					2005;20(2):45-9.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Watanabe</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Takeishi</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Hirono</surname>
							<given-names>O</given-names>
						</name>
						<name>
							<surname>Itoh</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Matsui</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Nakamura</surname>
							<given-names>K</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>C-reactive protein elevation predicts the occurrence of atrial
						structural remodeling in patients with paroxysmal atrial
						fibrillation</article-title>
					<source>Heart Vessels</source>
					<year>2005</year>
					<volume>20</volume>
					<issue>2</issue>
					<fpage>45</fpage>
					<lpage>49</lpage>
				</element-citation>
			</ref>
			<ref id="B26">
				<label>26</label>
				<mixed-citation>Ducceschi V, D'Andrea A, Liccardo B, Alfieri A, Sarubbi B, De Feo M,
					et al. Perioperative clinical predictors of atrial fibrillation occurrence
					following coronary artery surgery. Eur J Cardiothorac Surg.
					1999;16(4):435-9.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ducceschi</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>D'Andrea</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Liccardo</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Alfieri</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Sarubbi</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>De Feo</surname>
							<given-names>M</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Perioperative clinical predictors of atrial fibrillation
						occurrence following coronary artery surgery</article-title>
					<source>Eur J Cardiothorac Surg</source>
					<year>1999</year>
					<volume>16</volume>
					<issue>4</issue>
					<fpage>435</fpage>
					<lpage>439</lpage>
				</element-citation>
			</ref>
			<ref id="B27">
				<label>27</label>
				<mixed-citation>Verdecchia P, Angeli F. Natural history of hypertension subtypes.
					Circulation. 2005;111(9):1094-6.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Verdecchia</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Angeli</surname>
							<given-names>F</given-names>
						</name>
					</person-group>
					<article-title>Natural history of hypertension subtypes</article-title>
					<source>Circulation</source>
					<year>2005</year>
					<volume>111</volume>
					<issue>9</issue>
					<fpage>1094</fpage>
					<lpage>1096</lpage>
				</element-citation>
			</ref>
		</ref-list>
	</back>
</article>
